Nektar Therapeutics | NKTR - 债务利息支出



金融业
股票价格
USD
资产
USD 763.27M
现金及等价物
USD 149.58M
销售成本
USD 4.44M
流动资产
USD 589.04M
流动负债
USD 57.71M
债务
USD 0
股息收益率
0
EBIT
USD -38.26M
EBITDA
USD -38.9M
员工
137
EPS每股收益
USD -1.78
股本和储备
USD 576.22M
销售毛利
USD 10.86M
债务利息支出
USD 7.94M
利息收入
USD -0.18
贷款资金
USD 60.27M
市值
USD 10.91B
净收入
USD -44.9M
营业费用
USD 49.12M
营业利润
USD -38.26M
普通股股本
USD 29.47M
税前利润
USD -43.09M
销售收入
USD 10.86M
销售和管理费用
USD 11.87M
股票
USD 14.46M
贸易债权人
USD 10.03M
应收帐款人
USD 3.6M


债务利息支出 更改 日
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Baxter International USD 78M 20M 2026-03
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Cara Therapeutics -89.64M 128.67M 2025-12
Cipla INR 170.3M 39M 2026-06
Dr.Reddys Laboratories INR 1.26B 198M 2026-06
Eisai JPY 1.96B 409M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 5.59M 80K 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 525M 46M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Pfizer USD 667M 4M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Takeda JPY 63.85B 20.2B 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Xencor USD 7.35M 2.65M 2026-06